Shionogi & Co. (SGIOY)
(Delayed Data from OTC)
$11.79 USD
+0.14 (1.20%)
Updated Apr 29, 2024 02:36 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGIOY 11.79 +0.14(1.20%)
Will SGIOY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SGIOY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGIOY
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Upgraded to Buy: Here's Why
SGIOY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SGIOY
ViiV Healthcare announces FDA approval of Dovato for adolescents with HIV
ViiV Healthcare says interim data show superior efficacy of long-acting Cabenuva
ViiV’s long-acting HIV therapy outperforms daily therapy in Phase 3 trial
GSK says ViiV's cabotegravir study supports longer HIV dose interval
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial